Negative results from a major study of Merck's (MRK) cholesterol drug Tredaptive could spell the...


Negative results from a major study of Merck's (MRK) cholesterol drug Tredaptive could spell the end of sales of AbbVie's (ABBV) Niaspan, which is an extended-release form of the niacin vitamin that sold $911M in 2012. Niacin is used in Tredaptive along with Merk's laropiprant; Tredaptive failed to reduce strokes, deaths and heart attacks in patients with vascular diseases but did cause increased side effects. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs